Packages (Simulation)
Reagent Preparation
Image (I)
Image (II)
Certificate
Multiplex Assay Kit for Phospholipase A2 Group VII (LpPLA2) ,etc. by FLIA (Flow Luminescence Immunoassay)
PLA2G7; PAF-AH; PAFAH; Lp-PLA2; LDL-PLA2; Platelet Activating Factor Acetylhydrolase,Plasma; Phospholipase A2,Group VII; LDL-associated phospholipase A2; Phospholipase A2, Lipoprotein Associated
(Note: Up to 8-plex in one testing reaction)
- Product No.LMA867Mu
- Organism SpeciesMus musculus (Mouse) Same name, Different species.
- Sample TypeSerum, plasma and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length3.5h
- Detection Range0.02-20ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.007 ng/mL.
- DownloadInstruction Manual
- UOM 8Plex 7Plex 6Plex 5Plex 4Plex 3Plex 2Plex1Plex
- FOB
US$ 405
US$ 420
US$ 443
US$ 475
US$ 506
US$ 552
US$ 622
Result
For more details, please contact local distributors! US$ 778 Add to Price Calculator
Specificity
This assay has high sensitivity and excellent specificity for detection of Phospholipase A2 Group VII (LpPLA2) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Phospholipase A2 Group VII (LpPLA2) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Phospholipase A2 Group VII (LpPLA2) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Phospholipase A2 Group VII (LpPLA2) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 90-105 | 95 |
EDTA plasma(n=5) | 80-90 | 86 |
heparin plasma(n=5) | 96-104 | 101 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Phospholipase A2 Group VII (LpPLA2) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Phospholipase A2 Group VII (LpPLA2) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Phospholipase A2 Group VII (LpPLA2) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 80-93% | 99-105% | 99-105% | 79-94% |
EDTA plasma(n=5) | 89-103% | 80-92% | 83-97% | 98-105% |
heparin plasma(n=5) | 88-103% | 94-102% | 84-94% | 85-95% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
96-well plate | 1 | Plate sealer for 96 wells | 4 |
Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
Pre-Mixed Magnetic beads (22#:LpPLA2) | 1 | Analysis buffer | 1×20mL |
Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
GIVEAWAYS
INCREMENT SERVICES
Magazine | Citations |
Science & Sports | The effects of different intensity walking programs on serum blood lipids, high-sensitive C-reactive protein, and lipoprotein-associated phospholipase A2 in premenopausal women ScienceDirect: S0765159710000262 |
Metabolic Syndrome and Related Disorders | Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease Wiley: source |
34 | Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study PubMed: 22240497 |
PLoS ONE | Effects of Lipid-Lowering Drugs on Irisin in Human Subjects In Vivo and in Human Skeletal Muscle Cells Ex Vivo PubMed: PMC3759413 |
China Pharmacy | Influence of Tongfengtai Granules on Inflammatory Factor in Acute Gouty Arthritis Model Rats Source |
Atherosclerosis | Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients. Pubmed: 23958269 |
Journal of Diabetes Research | Lipoprotein-Associated Phospholipase A2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus Hindawi: 278063 |
Health | The Role of Asymmetric Dimethylarginine and Lipoprotein Associated Phospholipase A2 in Children and Adolescents with Dyslipidemia Scirp:Source |
Biology Bulletin | In vitro lipid-lowering and fibrinolytic effects of regulatory leucine-containing glyprolines in human blood Springer:Source |
Gynecol Endocrinol. | Lipoprotein-associated phospholipase A2 and AGEs are associated with cardiovascular risk factors in women with history of gestational diabetes mellitus. Pubmed:24397392 |
Journal of Diabetes Research | Lipoprotein-Associated Phospholipase A 2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus Pubmed:24818163 |
Metabolism. | Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes Pubmed:25034387 |
J Am Heart Assoc | Effect of Extended‐Release Niacin on High‐Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin‐Treated Patients PubMed: 26374297 |
Czecho-Slovak Dermatology / Cesko-Slovenska Dermatologie | V Ebscohost |
Endocrinol Metab (Seoul). | Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA2 in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome pmc:PMC4803547 |
Clin Pharmacol Ther. | Effect of dipyridamole on myocardial reperfusion injury: A double‐blind randomized controlled trial in patients undergoing elective coronary artery bypass surgery Pubmed:25773594 |
Lipids in Health and Disease | Effect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A 2 and secretory phospholipase A 2 in patients with newly … articles:10.1186 |
Acta Endocrinologica | SERUM LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN MALES WITH METABOLIC SYNDROME AND OBSTRUCTIVE SLEEP APNEA. jrnl:1841098 |
Biomarker for diagnosis of moyamoya disease : | |
JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION | Circulating fatty-acid binding-protein 4 levels predict CV events in patients after coronary interventions Pubmed: 32859455 |
chinese neurosurgical journal | Can admission lipoprotein-associated phospholipase A2 predict the symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage? |